MENTSH analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
1. A method of treating a disease and/or condition comprising:
administering a quantity of a mitochondrial-derived peptide to a subject afflicted with the disease and/or condition, wherein the mitochondrial-derived peptide is a polypeptide between 14 and 24 amino acids in length and comprises 75% or more sequence identity to SEQ ID NO:97 and contains a negatively charged amino acid as a substitute for residue threonine-7, residue serine-11, residue tyrosine-16, or a combination thereof of SEQ ID NO:97, or the mitochondrial-derived peptide comprises an amino acid sequence set forth in any of SEQ ID NOs: 1-22, 25-36, 43-47, 49-63, 65-87, 89, 91-93, 95, and 97,
wherein the disease and/or condition is characterized by reduced blood insulin level and/or reduced number or function of pancreatic beta islet cells, or the disease and/or condition comprises obesity or overweight.
2. The method of claim 1 , wherein the mitochondrial-derived peptide consists of an amino acid sequence as set forth in any one of SEQ ID NOs: 1-22, 25-36, 43-47, 49-63, 65-87, 89, 91-93, 95, and 97.
3. The method of claim 1 , wherein the mitochondrial-derived peptide consists of an amino acid sequence as set forth in SEQ ID NO:97.
4. The method of claim 1 , wherein the disease and/or condition comprises a disease and/or condition characterized by reduced blood insulin level and/or reduced number or function of pancreatic beta islet cells.
5. The method of claim 1 , wherein the disease and/or condition comprises type 1 or type 2 diabetes, gestational diabetes, pre-diabetes, insulin resistance, metabolic syndrome, impaired glucose tolerance or dyslipidemia.
6. The method of claim 5 , wherein the disease and/or condition further comprises retinopathy, neuropathy, or renal diseases.
7. The method of claim 1 , wherein the disease and/or condition comprises obesity or overweight.
8. The method of claim 1 , wherein the subject is Hispanic.
9. The method of claim 1 , wherein the subject is a carrier of a single nucleotide polymorphism (SNP) Rs28357981.
10. The method of claim 1 , wherein the subject expresses low amounts of the polypeptide as set forth in SEQ ID NO:97, measured in biological samples relative to a healthy normal subject without diabetes and/or obesity.
11. The method of claim 1 , wherein the mitochondrial-derived peptide possesses a post-translational modification or an artificial modification,
wherein said post-translational modification comprises formylation, phosphorylation, acetylation, or a combination thereof, and said artificial modification comprises pegylation, fatty-acid conjugation, polypeptide extension, or modification with IgG-Fc, carnitine palmitoyltransferase (CPT), human serum albumin (HSA), elastin-like polypeptide (ELP), transferrin, or albumin.
12. The method of claim 1 , wherein the mitochondrial-derived peptide is a polypeptide between 14 and 24 amino acids in length and comprises 75% or more sequence identity to SEQ ID NO:97, and the mitochondrial-derived peptide contains aspartic acid as a substitute for residue threonine-7, residue serine-11, residue tyrosine-16, or any combination thereof of SEQ ID NO:97.
13. A method of treating a disease and/or condition comprising administering a quantity of a mitochondrial-derived peptide to a subject afflicted with the disease and/or condition, wherein the mitochondrial-derived peptide comprises an amino acid sequence as set forth in SEQ ID NO:97, and wherein the disease and/or condition is characterized by reduced blood insulin level and/or reduced number or function of pancreatic beta islet cells, or the disease and/or condition comprises obesity or overweight.
14. A method of treating a disease and/or condition comprising administering a quantity of a mitochondrial-derived peptide to a subject afflicted with the disease and/or condition, wherein the mitochondrial-derived peptide is a polypeptide between 14 and 24 amino acids in length and comprises 75% or more sequence identity to SEQ ID NO:97, and the mitochondrial-derived peptide contains a negatively charged amino acid as a substitute for residue threonine-7, residue serine-11, residue tyrosine-16, or any combination thereof of SEQ ID NO:97, and wherein the disease and/or condition is characterized by reduced blood insulin level and/or reduced number or function of pancreatic beta islet cells, or the disease and/or condition comprises obesity or overweight.